How much did Gilead and Lakefront pay for Ouro Medicines?

The deal involved an upfront cash payment of $1,675 million, with up to $500 million in contingent milestone payments, which the companies will split equally.

What is the lead drug from the acquisition, and what does it do?

The lead candidate is gamgertamig (OM336), a BCMAxCD3 T cell engager designed for rapid depletion of plasma and B cells via a limited subcutaneous course, potentially offering durable disease control for severe antibody-mediated orphan diseases.

What regulatory designations does gamgertamig have?

Gamgertamig has received Fast Track and Orphan Drug Designations from the FDA, allowing for expedited development and regulatory support. Registrational studies are expected to start as early as 2027.

How are Gilead and Lakefront splitting responsibilities for gamgertamig?

Lakefront Biotherapeutics will handle ongoing and future Phase 1/2 studies, while Gilead Sciences leads late-stage registrational trials and retains sole worldwide commercialization rights, except for regions tied to prior agreements.

Image for illustrative purposes only. Not a real photo.

Gilead and Lakefront Biotherapeutics complete $1.68B acquisition of Ouro Medicines

Q: What was the purpose of Gilead Sciences (NASDAQ:GILD) and Lakefront Biotherapeutics (NASDAQ:LKFT) acquiring Ouro Medicines?

The acquisition aims to strengthen both companies’ inflammation and immunology portfolios with next-generation T cell engager therapies, primarily targeting autoimmune diseases such as AIHA and ITP.

Written by Brie CarterPublished Jun. 5 2026Last Updated Jun. 5 2026

Gilead Sciences (NASDAQ:GILD) and Lakefront Biotherapeutics (NASDAQ:LKFT) have finalized the acquisition of Ouro Medicines, a strategic move designed to bolster their respective inflammation and immunology portfolios with next-generation T cell engager therapies.

The deal, valued at an upfront cash payment of $1,675 million, also includes up to $500 million in contingent milestone payments, which the two companies have agreed to split equally.

The cornerstone of the acquisition is gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager.

The drug is engineered to achieve rapid and profound depletion of plasma and B cells through a limited course of subcutaneous administration.

This mechanism offers the potential to provide durable disease control in severe antibody-mediated orphan diseases, specifically autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).

Gamgertamig has already secured Fast Track and Orphan Drug Designations from the U.S. Food and Drug Administration, with registrational studies anticipated as early as 2027.

Under the collaborative framework, Lakefront will assume responsibility for the ongoing and future Phase 1/2 clinical studies of gamgertamig.

Gilead, meanwhile, will lead late-stage registrational efforts and retain sole worldwide commercialization rights, excluding specific regions associated with previous existing agreements.

As part of the commercial arrangement, Lakefront is set to receive tiered royalties ranging from 20% to 23% on global net sales of the therapy.

Beyond the lead candidate, Lakefront has in-licensed a preclinical portfolio of three additional autoimmune-focused programs originating from Ouro.

Gilead maintains an option to participate in these assets through a 50/50 profit-sharing arrangement, triggered upon the achievement of clinical proof-of-concept, at a cost of $75 million per program.

The transaction also includes a restructuring of the existing Option, License and Collaboration Agreement (OLCA) between Gilead and Lakefront.

This modification provides Lakefront with the flexibility to deploy at least $500 million of its independent capital toward strategic transactions or share repurchases, independent of the Ouro deal.

With a robust balance sheet—projected at approximately €2 billion by the end of 2026—Lakefront intends to utilize the Ouro pipeline as the foundation for its long-term research and development strategy.